A novel HIV vaccine candidate induces neutralising antibodies after a single dose in primates, potentially accelerating HIV prevention.

The trial is taking place at the Desmond Tutu HIV Foundation, located at Groote Schuur Hospital in Cape Town. It is the first ...

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...

South Africa has begun the first human trials of a locally developed HIV vaccine to defeat a virus that still kills around one person per minute worldwide.

So far, there is no "magic bullet" to cure HIV for good, but scientists are making rapid progress.

The closest thing we have to an HIV vaccine has hit the market – but less than a tenth of the doses needed to change the course of the pandemic will reach the people who need them, new figures suggest ...

Researchers developed a DNA-scaffolded vaccine that achieves the first step in generating a significant population of B cells that produce broadly neutralizing antibodies against HIV.

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

New research from Boston Medical Center found that people living with HIV that have had pulmonary tuberculosis had broader and more potent HIV antibody responses and differences in HIV sequences ...

The BRILLIANT 011, a first-in-human clinical trial, was officially launched at the Desmond Tutu HIV Foundation (DTHF) ...